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Sudarshan AnandAbstract
Development of the vasculature is a complex, dynamic process orchestrated by a balance of pro and
anti-angiogenic signaling pathways. The same signaling pathways are mis-regulated and exploited during
pathological angiogenesis in cancer, inflammation and cardiovascular diseases and contribute to disease
progression. In the last decade, small non-coding RNA molecules termed microRNAs (miRs) have emerged as key
regulators of several cellular processes including angiogenesis. It is becoming clear that miRs function in complex
networks and regulate gene expression both at the mRNA and protein levels thereby altering cellular signaling
responses to specific stimuli. In the vasculature, miRs can function either in a pro-angiogenic manner and
potentiate angiogenesis or act as anti-angiogenic miRs by enhancing cell death and decreasing endothelial
proliferation. This review aims to provide an update on how microRNAs regulate gene expression and illustrate miR
function in the vasculature with a discussion of potential applications of miRs as anti-angiogenic therapeutics.
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growing list of sophisticated functions. Endothelial cells
have been implicated in diverse functions ranging from
release of cytokines during influenza infections [1],
maintenance of hematopoietic stem cells [2], to adipo-
genesis of both white and brown fat cells [3]. Suffice to
say that endothelial cells have moved beyond the label of
‘cells lining the blood vessels’. Given such a broad array
of functions, it is not surprising that there are multiple
signaling networks [4] with several checks and balances
that control endothelial responses to external perturba-
tions. Over the last few years, microRNAs have emerged
as critical regulators of signaling pathways in multiple
cell types including endothelial and perivascular cells.
There are several excellent reviews that have summar-
ized the different miRs involved in vascular function
during development and disease [5-7]. Here, I will focus
on providing a broad framework to understand miR
function and illustrate features of specific miRs in the
regulation of angiogenesis.Correspondence: suanand@ucsd.edu
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MicroRNAs (miRs) are small 20-24 nucleotide long
RNAs that regulate gene expression by binding to
mRNAs. miRs represent about 1-2% of the genes in se-
veral species including mammals [8]. Current version of
miRbase reports 1600 precursors and 2042 mature miR
sequences for humans and 855 precursors and 1281 ma-
ture miRs for mice [9]. It is estimated that miRs could
well regulate 30-50% of protein coding genes. A large
portion of miRs is encoded in introns of genes or in
intergenic regions. They are transcribed as a primary
miR (pri-miRNA) transcript by RNA polymerase II in
conjunction with specific transcription factors that bind
to a region upstream similar to a protein coding gene.
These miR transcripts are then cleaved by a heterodimer
of dsRNA binding proteins, Drosha and DiGeorge Syn-
drome Critical Region 8 (DGCR8), releasing a 55-70 nt
small RNA hairpin termed pre-miR. This RNA hairpin is
then exported out of the nucleus by Exportin-5 and
Ran-GTP. In the cytoplasm, another RNAse III enzyme,
Dicer cleaves the pre-miRs to generate 22nt duplex
RNAs. These are now mature miRs that get incorpo-
rated into RNA induced silencing complex (termed
RISC) consisting of two major classes of proteins Argo-
naute and GW182. While this is the canonical pathwayhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ternative pathways depending on cell type, organism and
biological contexts [10,11]. For example, the loss of
Dicer leads to a more significant phenotype in the brain
and embryonic stem cells compared to the loss of either
Drosha or DGCR8. Similarly, loss of Dicer in the vascu-
lature has a more profound effect than the loss of
Drosha suggesting there may be Drosha independent
mechanisms of miR biogenesis [12]. These observations
highlight the degree of complexity in the different RNA
processing pathways.How do miRs work?
When miRs were initially described, it was proposed that
miRs bind to target mRNAs using a seed sequence con-
sisting of 6-8 continuous bases and a few more comple-
mentary bases along the miR sequence. In plants, miRs
have almost perfect complementarity with the target
mRNA and these targets undergo direct RNAse
mediated cleavage [13]. However, the mammalian miRs
rarely had perfect complementarity with their targets.
Therefore, it was hypothesized that mammalian miRs
suppressed translation of target mRNAs leading to a de-
crease in target proteins [14]. Interestingly, recent work
based on mRNA arrays and ribosome profiling has
shown that miRs can also cause mRNA decay in mam-
malian cells and this is likely due to deadenylation of the
mRNA [15]. The relative contributions of mRNA decay
and translation inhibition mechanisms in suppressing
the target protein levels remains an area of active inves-
tigation [16].What do miRs do that proteins cannot do?
It has been postulated that miRs maintain robustness of
gene expression by insulating biological systems against
noise [17]. For example, miR-1 and miR-7 in Droso-
phila insulate muscle differentiation and photoreceptor
determination from external perturbations [18,19].
While there are other regulatory mechanisms that con-
trol gene expression programs such as transcriptional
regulators, epigenetic modifications etc, miRs offer a
unique advantage by regulating gene expression in the
cytoplasm. Moreover, there are miRs that could be
upregulated rapidly in cells up to several thousand co-
pies per cell thereby achieving greater potency than
otherwise possible. There have been simulations that
demonstrate that miR mediated feed forward loops are
more effective than transcriptional repressors in buffer-
ing gene expression against external perturbations [20].
Finally, the fact that miRs can regulate multiple targets,
often several of them in a single pathway, makes them
a more effective tool to modulate gene expression in re-
sponse to specific stimuli.Are miRs essential in the vasculature?
The importance of miRs in vascular development was
apparent based on loss-of-function studies of Dicer.
Dicer hypomorphic mice had severe vascular deform-
ation in both the embryo and the yolk sac and died at
E12.5-E-14.5 [21]. Similarly, loss of Dicer led to pericar-
dial edema and impaired circulation in zebrafish embryos
[22]. Moreover, endothelial specific deletion of Dicer in
mice decreased postnatal angiogenesis in response to
multiple stimuli [23]. Similarly, inducible deletion of
Dicer in vascular smooth muscle cells in mice led to
impaired contractility, smooth muscle differentiation and
vascular remodeling [24]. Taken together, these early
studies established that the loss of Dicer and the con-
comitant loss of miR processing activity caused signifi-
cant structural and functional defects in the vascular
compartment.Which miRs regulate vascular function?
The first study to report a putative role for specific
microRNAs in endothelial cells was performed by
Poliseno et al. The authors used microarray based profi-
ling and identified the most abundant miRs in HUVECs
[25]. They reported that several miRs were predicted to
target angiogenic growth factor receptors and character-
ized miR-221/222 as negative regulators of angiogenesis.
One of the earliest miRs reported to affect endothelial
function in vivo was miR-126. miR-126 is the most abun-
dant microRNA in endothelial cells. Loss-of-function
studies in mice and Zebrafish highlighted that miR-126 is
important for developmental and pathological angioge-
nesis and implicated Sprouty Related EVH Domain con-
taining protein 1(SPRED1), a negative regulator of
Vascular Endothelial Growth Factor (VEGF) signaling, as
a critical target of miR-126 [26,27]. Interestingly, experi-
ments in Zebrafish demonstrate that blood flow can upre-
gulate miR-126 via activation of Klf2, a mechanosensitive
transcription factor [28]. Png and colleagues reported
recently that miR-126 regulates endothelial cell recruit-
ment to metastatic breast cancer cells, in vitro and in vivo
[29]. They showed that miR-126 downregulated a complex
network of targets IGFBP2, PITPNC1a and MERTK and
suppressed metastatic endothelial recruitment, metastatic
angiogenesis and metastatic colonization. These experi-
ments suggest that the non-endothelial miR-126 can still
impact angiogenesis albeit in an anti-angiogenic manner.
While the majority of miRs that have been reported
function as pro-angiogenic miRs, miR-17 ~ 92 cluster, a
well-characterized group of miRs plays a critical role as
a negative regulator of angiogenesis [30,31]. Bonauer et
al showed that miR-92a has an anti-angiogenic effect
partly through targeting the integrin subunit α5. Loss of
miR-92a improved functional recovery after myocardial
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growth [30,31].
The miRs highlighted here are examples to illustrate
the diverse ability of miRs in manipulating endothelial
function. We and others have reviewed the many differ-
ent miRs that play a role in vascular function [32,33].
Some of the prominent miRs in endothelial cells and
smooth muscle cells, their functions and target genes
are listed in the table below (Table 1).
miR-132 in endothelial and perivascular cells
We identified miR-132 as an angiogenic miR that func-
tions by regulating p120RasGAP and Ras signaling path-
ways using a human embryonic stem cell vasculogenesis
model and primary endothelial cells [36]. We demon-
strated that reciprocal expression of miR-132 and its
target p120RasGAP correlated with pathological angio-
genesis in human breast tumors and in human hemangi-
omas. Targeted delivery of an anti-miR-132 decreased
angiogenesis and tumor progression in mouse tumor
xenograft models. Consistent with our observations in
vascular endothelial cells, Lagos et al reported that miR-
132 is upregulated with similar kinetics and plays a key
role in lymphatic endothelial cells during viral infections
[44]. More recently, Mulik et al showed that miR-132
expression was upregulated by a VEGF-A and IL-17
dependent mechanism after ocular infection with
Herpes Simplex Virus (HSV) [45]. The authors demon-
strated that in vivo silencing of miR-132 by the provision
of anti-miR-132 nanoparticles to HSV-infected mice led
to reduced corneal neovascularization and diminished
lesions. Taken together, these observations indicate that
miR-132 may play an important role in pathological
neovascularization downstream of multiple triggers in-
cluding tumor-derived growth factors, viral infections
and inflammation.
Subsequent to our work, other groups have reported
the function of miR-132 in perivascular cells. NatarajanTable 1 Summary of different miRs and their roles in vascula
microRNA Role
Let-7 family Increases EC proliferation, migration
miR-126 Enhances VEGF signaling in ECs
miR-132 Enhances growth factor signaling
miR-210 Stimulates tube formation and migration
miR-221/222 Inhibits cell proliferation, Anti-angiogenic
miR-296 Inhibits growth factor receptor recycling and degradation
miR-424 Stablizes HIF-1, proangiogenic
miR-92a Anti-angiogenic. Inhibition enhanced neovascularization in
ischemic tissues
miR-143/145 Critical for VSMC differentiation
miR-26a Increases VSMC proliferationand colleagues showed time- and dose-dependent up-
regulation of miR-132/212 by Ang II through the Ang II
Type 1 receptor [37]. They identified phosphatase and
tensin homolog (PTEN) as a novel target of miR-132
and demonstrated that miR-132 induces monocyte
chemoattractant protein-1 in rat VSMC. The authors
demonstrated the presence of a positive feedback loop
where phosphorylation of cAMP Response Element
Binding protein (CREB) led to miR-132 transcription;
miR-132 overexpression resulted in enhanced CREB
phosphorylation via p120RasGAP downregulation. In
addition, the authors observed that aortas from Ang II-
infused mice displayed similar up-regulation of miR-
132/212 and monocyte chemoattractant protein-1 and
concluded that miR132/212 can serve as a novel cellular
node to fine-tune and amplify Ang II actions in VSMC.
Another recent study [46] showed that miR-132 was
constitutively expressed and secreted by saphenous vein
pericytes and facilitates cardiac regeneration following
myocardial infarction. Both CREB and miR-132 were
activated by treatment of these cells by VEGF-B or
hypoxia/starvation. The authors report that miR-132 is
secreted by these pericytes and can act as a paracrine
activator of cardiac healing, highlighting a non-cell au-
tonomous role for miR-132.
What triggers miR expression?
The vasculature is exposed to several stimuli and stres-
sors during developmental and pathological angiogenesis
that trigger distinct miR expression profiles. For in-
stance, miR-210 and miR-424 have been shown to be
upregulated in response to hypoxia [38,41]. We have
observed specific miRs upregulated in response to angio-
genic growth factors VEGF and bFGF [36]. Other studies
have also documented miRs regulated by Notch pathway
signaling [47] and cytokines such as IL-3 [48]. These
stimuli subsequently trigger miR expression via classic
signal transduction pathways and transcription factors.r cells
Target(s) References
TIMP-1 [34]






















Figure 1 A simple network of VEGF and Notch signaling
regulated by microRNAs. miRs identified in angiogenic screens
[36] were cross-referenced with prediction programs for their ability
to target specific nodes of a protein interaction network. Several
miRs predicted to target angiogenic proteins were significantly
downregulated in the screens (blue, italics). The illustration depicts
how the loss of a few miRs that target positive regulators of
angiogenesis can amplify a pro-angiogenic cascade.
Table 2 Different strategies to inhibit miR function
in vivo
Reagent Description
AntagomiRs Cholesterol conjugated 2’-O-Methyl antisense
oligonucleotides
LNA-AntimiRs Locked nucleic acid based antisense oligos
miR sponges Oligos with multiple miR binding sites to act as
competitive inhibitors
miR-masks Oligos with gene specific sequences complementary to
miR binding sites
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tiple cell types including endothelial cells, vascular
smooth muscle cells and neurons [36,37,49]. Harris et al
have shown that miR-126 is transcribed by Ets family
members Ets-1 and Ets-2 [50]. Interestingly, Nicoli et al
demonstrated that blood flow induced mechanosensitive
transcription factor Klf2a can also transcribe miR-126
during aortic arch development in Zebrafish [28]. While
the factors that induce miR expression have been widely
characterized, regulatory sequences such as promoters
for specific miRs have not yet been well defined and re-
main an area of considerable interest.
How do miR-target networks regulate angiogenic
signals?
While initial reports of miR function focused on one or
two specific targets of miRs, it is becoming clear that the
biology of miR-target interaction is much more compli-
cated than simple RNA-RNA binding that is the basis of
target prediction algorithms. Recent evidence suggests
that evolution of conserved miR/target networks can exert
powerful influence on biological functions [51]. Given
these considerations, one can envision future work in
understanding physiological roles of miRs will include sys-
tems level analysis of multiple miRs and targets.
For example, it is well established that VEGF and
Notch signaling are key regulators of developmental
angiogenesis. Mapping of a few receptors, ligands and
transcription factors on this pathway using STRING
database [52] shows how these molecules interact with
each other. Our work identified several microRNAs that
were regulated during growth factor signaling in endo-
thelial cells and human ES cell vascular development.
Some of these miRs from our screen have been pre-
dicted to target specific NOTCH or VEGF signaling
components Figure 1. Interestingly, it appears that the
miRs that were downregulated (blue, italicized) are
predicted to target NOTCH or VEGF signaling com-
ponents. This observation implies that downregulation
of a few miRs can amplify a pro-angiogenic signaling
network. Conversely, upregulation of miRs such as
miR-132 and miR-126 can potentiate angiogenesis by
targeting negative regulators of VEGF signaling such
as p120RasGAP, SPRED1 etc. This network illustrates
a cascade of miR transcription or decay events that
can function in a positive feedback loop to amplify
signals and sustain angiogenic responses Figure 1.
Are miRs ‘druggable’ targets in human diseases?
Although miRs were discovered only about a decade
ago, they have rapidly progressed to the verge of clinical
utility. In fact, there are currently 124 clinical trials listed
on microRNAs with 72 of them focused on cancer
patients [53]. Many of these trials have focused onutilizing miR signatures for diagnostics across a
spectrum of diseases. The first phase I trial of a micro-
RNA therapeutic against HCV has shown excellent
safety profile, good efficacy and has moved to Phase II
trials highlighting that this novel class of drugs may have
significant clinical potential [54]. Currently there are a
number of different therapeutic strategies [55,56] that
are being evaluated in preclinical models to inhibit miRs
as described in Table 2.
Although these are exciting times for discovery of
miRs and their applications, there are certain limitations
to therapeutic targeting of miRs in the context of com-
plex pathologies such as cancer.
1) Targeting anti-miR therapeutics to specific tissues.
Naked injection of anti-miRs or cholesterol
conjugated antagomiRs typically results in excellent
delivery to the liver. However, targeting specific anti-
miRs to tissues such as tumor vasculature or sites of
ischemic injury is still challenging. Nanoparticles and
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be useful in delivering anti-miRs for specific
applications [55].
2) The delivery of double stranded miR/miR mimics to
tumor cells is still challenging and faces similar
roadblocks as siRNA therapies. Recent work that
shows that a single guide strand of RNA is sufficient
to mediate RNA interference is exciting. This could
lead to more efficient delivery of miRs to tumor cells
in vivo [57,58].
3) The mechanism of action of miRs/anti-miRs is
complicated by the number of potential targets that
could be affected by a miR. There are discrepancies
between prediction algorithms and experimental
observations, not to mention cell type specific effects
and differences in targets between human and
mouse. Therefore, global analysis of mRNA and
protein levels in cells/tissues that are targeted by the
miR therapeutics may be warranted to understand
the mechanism(s) of action.
miR inhibitors as anti-angiogenic agents in ocular
disease
miR inhibitors can be effective as simple oligonucleotides
in ocular disease without the above mentioned require-
ments for specific delivery systems. Anti-angiogenic the-
rapy, most notably, anti-VEGF antibody has shown
significant therapeutic benefit in patients with Age-related
Macular Degeneration (AMD) and consequently garnered
several accolades including ‘Science-Breakthrough of the
year 2006’ and the 2010 Lasker award [59]. There is proof-
of-principle that targeting the VEGF pathway in the eye
using single-strand RNA-based therapies can effectively
block pathological neovascularization in humans, such as
the VEGF RNA-aptamer Macugen/pegaptanib, which is
approved for macular degeneration [60]. While the suc-
cess of anti-VEGF approaches have been remarkable, it
is not clear whether there are any long-term effects of
targeting VEGF. Recently, Kurihara, Westenskow et al
show that conditional deletion of Vegfa in adult mouse
retinal pigmented epithelial (RPE) cells leads to vision
loss and ablation of the choriocapillaris, the major
blood supply for the outer retina and photoreceptor
cells [61]. It appears that the loss of VEGF resulted in
the downregulation of multiple angiogenic genes rele-
vant for physiological and pathological angiogenesis.
Therefore the authors conclude that endogenous VEGF
provides trophic support necessary for retinal function.
Interestingly, our work has identified several promising
miRs that are downstream of VEGF signaling pathways
that can be pursued as alternatives to VEGF inhibitors
in the eye. We demonstrated that anti-miR-132 is able
to decrease developmental angiogenesis in neonatal re-
tinas without affecting established vasculature [36]. Sincethe intraocular injection of anti-miR reagents selectively
interferes with angiogenic endothelial cells that have
upregulated miR-132 and not the normal quiescent vas-
culature, it is likely that this strategy will not have the
global effects observed with VEGF ablation. In collabo-
ration with Friedlander and colleagues, we have now
observed that anti-miR-132 is a potent inhibitor of
pathological neovascularization in the eye in various
mouse models (Westenskow and Friedlander, submitted).
It remains to be seen if long term use of anti-miR-132 and
more broadly anti-angiogenic miRs, can circumvent
some of the adverse effects associated with the lack of
VEGF in the eye while effectively inhibiting pathological
neovascularization.
Conclusions
The emergence of miRs as regulators of gene expression
has undoubtedly altered our understanding of how di-
verse stimuli affect function in the vasculature. miRs
have been shown to alter specific signaling pathways that
affect proliferation, differentiation, migration and cell
survival in endothelial cells and smooth muscle cells.
The challenges moving forward would be to integrate
the different miRs and their target networks in the
stimulus–response cycles of the vasculature and to
understand how manipulating one or more miRs can
alter cell function in vitro and in vivo. The therapeutic
potential of these molecules as anti-angiogenic agents
has been shown in multiple animal models and we may
be just a few years away from using them to target aber-
rant angiogenesis in humans.
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